LLY

791.36

-1.92%↓

JNJ

152.37

-1.77%↓

NVO

74.38

-3.34%↓

ABBV

185.23

-2.89%↓

UNH

308.61

+0.35%↑

LLY

791.36

-1.92%↓

JNJ

152.37

-1.77%↓

NVO

74.38

-3.34%↓

ABBV

185.23

-2.89%↓

UNH

308.61

+0.35%↑

LLY

791.36

-1.92%↓

JNJ

152.37

-1.77%↓

NVO

74.38

-3.34%↓

ABBV

185.23

-2.89%↓

UNH

308.61

+0.35%↑

LLY

791.36

-1.92%↓

JNJ

152.37

-1.77%↓

NVO

74.38

-3.34%↓

ABBV

185.23

-2.89%↓

UNH

308.61

+0.35%↑

LLY

791.36

-1.92%↓

JNJ

152.37

-1.77%↓

NVO

74.38

-3.34%↓

ABBV

185.23

-2.89%↓

UNH

308.61

+0.35%↑

Search

Cogent Biosciences Inc

Cerrado

7.6 1.47

Resumen

Variación precio

24h

Actual

Mínimo

7.31

Máximo

7.81

Métricas clave

By Trading Economics

Ingresos

-4.1M

-72M

BPA

-0.525

Empleados

205

EBITDA

-1.2M

-74M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 meses

+133.05% upside

Dividendos

By Dow Jones

Próximas Ganancias

5 ago 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

172M

806M

Apertura anterior

6.13

Cierre anterior

7.6

Puntuación técnica

By Trading Central

Confianza

Bearish Evidence

Cogent Biosciences Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

17 jun 2025, 14:44 UTC

Adquisiciones, fusiones, absorciones

Justice Department Orders Safran to Sell Assets to Proceed with Buy of Collins Aerospace Business

17 jun 2025, 23:43 UTC

Charlas de Mercado

Nikkei May Fall Amid Uncertainty Over Israel-Iran Conflict -- Market Talk

17 jun 2025, 23:34 UTC

Charlas de Mercado

Gold Steady, Underpinned by Ongoing Geopolitical Tensions -- Market Talk

17 jun 2025, 23:22 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

17 jun 2025, 23:22 UTC

Charlas de Mercado

Global Energy Roundup: Market Talk

17 jun 2025, 23:22 UTC

Charlas de Mercado

Meridian Energy Set to Draw Line Under 'Annus Horribilis' -- Market Talk

17 jun 2025, 23:17 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Tourism Holdings Likely to Seek Higher Offer -- Market Talk

17 jun 2025, 23:05 UTC

Charlas de Mercado

Fletcher Building Could Signal Improved Shareholder Returns -- Market Talk

17 jun 2025, 23:05 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

17 jun 2025, 22:58 UTC

Charlas de Mercado

Australian Treasurer Chalmers Expected to Outline Second-Term Reform Agenda -- Market Talk

17 jun 2025, 22:55 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

XRG Has a Good Argument for Regulatory Approval of Santos Deal -- Market Talk

17 jun 2025, 22:31 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Lifeway Foods CEO Not Surprised by Takeover Interest -- Market Talk

17 jun 2025, 22:14 UTC

Principales Movimientos del Mercado

Bitdeer Technologies Group Shares Fall on Note Offering

17 jun 2025, 19:49 UTC

Charlas de Mercado

Natural Gas Slow Down Gains -- Market Talk

17 jun 2025, 19:34 UTC

Charlas de Mercado

Oil Rises On Israel-Iran Conflict Uncertainty -- Market Talk

17 jun 2025, 19:10 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

17 jun 2025, 19:10 UTC

Charlas de Mercado

Dollar Strengthens, Treasury Yields Fall in Risk-Off Trade -- Market Talk

17 jun 2025, 18:41 UTC

Charlas de Mercado

Slowdown in US Consumer Spending Expected -- Market Talk

17 jun 2025, 18:15 UTC

Charlas de Mercado

Gold Inches Down as Profit-Taking Seen -- Market Talk

17 jun 2025, 17:44 UTC

Charlas de Mercado

Analysts Forecast Record-High Ethanol Output -- Market Talk

17 jun 2025, 16:37 UTC

Charlas de Mercado

A Buy-Canadian Policy Could Support Steel Producers -- Market Talk

17 jun 2025, 16:30 UTC

Charlas de Mercado

Market Talk Roundup: Latest on U.S. Politics

17 jun 2025, 16:30 UTC

Charlas de Mercado

Canada Seen Likely to Drop Digital-Services Tax -- Market Talk

17 jun 2025, 16:15 UTC

Charlas de Mercado

Global Commodities Roundup: Market Talk

17 jun 2025, 16:15 UTC

Charlas de Mercado

Base Metal Prices Mixed on Risk-Off Sentiment -- Market Talk

17 jun 2025, 16:12 UTC

Charlas de Mercado

Gold Futures Fall as Safe-haven Demand Retreats -- Market Talk

17 jun 2025, 14:54 UTC

Charlas de Mercado

Oil Rises on Continued Israel-Iran Conflict -- Market Talk

17 jun 2025, 14:47 UTC

Charlas de Mercado

European Gas Climbs on Middle East Risks, EU Russian Ban Proposal -- Market Talk

17 jun 2025, 14:41 UTC

Charlas de Mercado

Natural Gas Extends Climb -- Market Talk

17 jun 2025, 14:40 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

Comparación entre iguales

Cambio de precio

Cogent Biosciences Inc Esperado

Precio Objetivo

By TipRanks

133.05% repunte

Estimación a 12 meses

Media 16.5 USD  133.05%

Máximo 25 USD

Mínimo 7 USD

De acuerdo con 9 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Cogent Biosciences Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

9 ratings

7

Comprar

2

Mantener

0

Vender

Puntuación técnica

By Trading Central

4.88 / 5.87Soporte y Resistencia

Corto Plazo

Bearish Evidence

Medio plazo

Weak Bearish Evidence

Largo Plazo

Strong Bearish Evidence

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Cogent Biosciences Inc

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.